Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy

Diabetologia

Volumn 48, Issue 1, 2005, Pages 149-155

  Tarnow, L ^a   Hildebrandt, P ^b   Hansen, B V ^a   Borch Johnsen, K ^a,c   Parving, H H ^c  

^a STENO DIABETES CENTER   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Cardiovascular mortality; Diabetic nephropathy; Mortality; NT proBNP; Type 1 diabetes

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CIRCULATION; CLINICAL OBSERVATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; FEMALE; FOLLOW UP; HEMOCONCENTRATION; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEINURIA; SEQUENCE ANALYSIS;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 12944280254     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1595-0     Document Type: Article

References (32)

1. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496-501
2. Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590-596
3. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk-factors. Diabetologia 30:144-148
4. de Lemos JA, McGuire DK, Drazner MH (2003) B-Type natriuretic peptide in cardiovascular disease. Lancet 362:316-322
5. Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-167
6. Gustafsson F, Badskjær J, Hansen FS, Poulsen AH, Hildebrandt P (2003) Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 3:141-146
7. Groenning BA, Nilsson JC, Sondergaard L et al (2002) Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 143:923-929
8. Gardner RS, Özalp F, Murday AJ, Robb SD, McDonagh TA (2003) N-Terminal pro-brain natriuretic peptide - a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24:1735-1743
9. de Lemos JA, Morrow DA, Bentley JH et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014-1021
10. Tarnow L, Cambien F, Rossing P et al (1995) Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 38:798-803
11. Tarnow L, Cambien F, Rossing P et al (1995) Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44:489-494
12. Parving H-H, Østerby R, Ritz E (2003) Diabetic nephropathy. In: Brenner BM (ed) The kidney, 7th edn. WB Saunders, Philadelphia, pp 1777-1818
13. Feldt-Rasmussen B, Dinesen B, Deckert M (1985) Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45:539-544
14. Bröchner-Mortensen J, Rödbro P (1976) Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35-45
15. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461-470
16. Pfeffer MA, Swedberg K, Granger CP et al (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362:759-766
17. Knowles HC, Guest GM, Lampe J, Kessler M, Skillman TG (1965) The course of juvenile diabetes treated with unmeasured diet. Diabetes 14:239-273
18. Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H (1996) Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. Br Med J 313:779-784
19. Tarnow L, Rossing P, Gall M-A, Nielsen FS, Parving H-H (1994) Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 17:1247-1251
20. Hildebrandt P, Boesen M, Olsen MH, Wachtell K, Groenning BA (2004) N-Terminal pro brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 6:313-317
21. Sato A, Tarnow L, Parving H-H (1999) Prevalence of left ventricular hypertrophy in type 1 diabetic patients with diabetic nephropatliy. Diabetologia 42:76-80
22. Epshteyn V, Mudalier S, Morrison K et al (2003) Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26:2081-2087
23. Srivastava PM, Calafiore P, Burrell LM (2003) The role of BNP in the diagnosis of cardiac dysfunction in subjects with diabetes mellitus. Diabetologia 46(Suppl 2):A359 (Abstract)
24. de Lemos JA, Morrow DA (2002) Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation 106:2868-2870
25. Morrow DA, de Lemos JA, Sabatine MS et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 42:1264-1272
26. James SK, Lindahl B, Siegbahn A et al (2003) N-Terminal probrain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease - a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 108:275-281
27. Wang TJ, Larson MG, Levy D et al (2003) Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108:13-16
28. Candido R, Forbes JM, Thomas MC et al (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785-792
29. Naganuma T, Sugimura K, Wada S et al (2002) The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 22:437-444
30. Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655-663
31. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126-1130
32. Mueller C, Scholer A, Laule-Kilian K et al (2004) Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350:647-654